XNASSCPH
Market cap171mUSD
Dec 23, Last price
3.42USD
1D
0.88%
1Q
-28.30%
IPO
-75.83%
Name
scPharmaceuticals Inc
Chart & Performance
P/E
—
P/S
12.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
15.72%
Rev. gr., 5y
%
Revenues
14m
Net income
-55m
L+46.09%
CFO
-59m
L+71.34%
Earnings
Mar 11, 2025
Profile
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 13,593 | ||||||||
Cost of revenue | 68,989 | 36,625 | 26,261 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (55,396) | (36,625) | (26,261) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 681 | 2,452 | |||||||
Tax Rate | |||||||||
NOPAT | (55,396) | (37,306) | (28,713) | ||||||
Net income | (54,810) 46.09% | (37,519) 23.07% | (30,486) -11.36% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 14,038 | 47,711 | (30) | ||||||
BB yield | -5.81% | -23.46% | 0.02% | ||||||
| Debt | |||||||||
Debt current | 352 | 567 | 10,281 | ||||||
Long-term debt | 41,551 | 37,375 | 7,830 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | 4,034 | 7,545 | 367 | ||||||
Net debt | (34,110) | (80,426) | (57,349) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (59,244) | (34,577) | (27,151) | ||||||
CAPEX | (40) | (21) | (9) | ||||||
Cash from investing activities | 19,965 | (45,859) | 32,130 | ||||||
Cash from financing activities | 14,850 | 77,229 | (2,530) | ||||||
FCF | (60,305) | (37,447) | (28,284) | ||||||
| Balance | |||||||||
Cash | 76,013 | 118,368 | 75,460 | ||||||
Long term investments | |||||||||
Excess cash | 75,333 | 118,368 | 75,460 | ||||||
Stockholders' equity | (281,343) | (226,501) | (189,696) | ||||||
Invested Capital | 362,967 | 44,829 | 17,995 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 38,514 | 28,359 | 27,352 | ||||||
Price | 6.27 -12.55% | 7.17 42.83% | 5.02 -5.10% | ||||||
Market cap | 241,481 18.76% | 203,330 48.09% | 137,306 5.64% | ||||||
EV | 207,371 | 122,904 | 79,957 | ||||||
EBITDA | (54,770) | (36,157) | (25,823) | ||||||
EV/EBITDA | |||||||||
Interest | 8,123 | 3,302 | 2,575 | ||||||
Interest/NOPBT | |||||||||